HIGHLIGHTS
- who: Stéphane Dalle from the France France have published the research work: Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study, in the Journal: (JOURNAL) of January/19,/2012
- what: The authors report the estimated incidence and severity of TRAEs in patients treated with ipilimumab in the postapproval setting using CTCAE criteria. The authors assess long-term quality of life (QoL) in the overall patient population. In this study, tumor response was based on the last tumor assessment recorded with a nonmissing assessment date during the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.